The U.S. Food and Drug Administration (FDA) has upgraded a recall of tomatoes sold in three southern states to a Class I recall, the most serious level, because the tomatoes may be contaminated ...

Cases of myocarditis are more severe and more common after a COVID infection than after receiving the COVID vaccine, health officials have said.

Obstructive sleep apnoea (OSA) is increasingly recognised as a highly heterogeneous disorder.1 Drivers of the disease process are various and include anatomical traits such as upper airway narrowing ...

A food recall of nearly 6,000 cases of cookies distributed across 15 states has been given the U.S. Food and Drug Administration's (FDA) second-highest risk level. Carley's Inc. voluntarily ...

Nestlé and Conagra said they would stop using FD&C colors in products, as Health Secretary Robert F. Kennedy Jr. has urged the industry to stop using synthetic food dyes.

--Grace Therapeutics, Inc., a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant ...

The Department of Health and Human Services and the Food and Drug Administration announced on Tuesday a series of measures to phase out eight artificial food dyes.

FDA assigns PDUFA target action date of January 31, 2026 WARREN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a ...

KalVista has become the latest biotech to face delays to FDA decision-making, as the agency blames a “heavy workload” for pushing back a PDUFA date.

Sarepta’s shares crashed 41% in premarket trading Monday morning to $21.01 after the biotech reported a second death from acute liver failure, a known side effect of adeno-associated virus-based gene ...

Sun Pharmaceutical Industries has informed that the US FDA conducted a Good Manufacturing Practices (GMP) inspection of Sun Pharmaceutical Industries Limited's Halol facility (Gujarat, India) from 02 ...

Ravindra Uppaluri, MD, PhD, discusses the background regarding locally advanced head and neck cancer and what the trial design of KEYNOTE-689 entailed. On June 12, 2025, the FDA granted approval to ...